Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients

被引：0

作者：

Fu, Chengcheng ^{[1
]}

You, Hongying ^{[1
]}

Jin, Song ^{[1
]}

Wang, Panfeng ^{[2
]}

Yan, Lingzhi ^{[1
]}

Zhang, Liying ^{[3
]}

Lu, Tingting ^{[4
]}

Gao, Xiao ^{[5
]}

Jiang, Lei ^{[6
]}

Qiu, Hongchun ^{[7
]}

Shang, Jingjing ^{[1
]}

Zhai, Yingying ^{[1
]}

Yao, Weiqin ^{[1
]}

Yan, Shuang ^{[1
]}

Yan, Zhi ^{[1
]}

Wu, Depei ^{[1
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China

[2] Soochow Hopes Hematonosis Hosp, Suzhou, Peoples R China

[3] Soochow Univ, Affiliated Hosp 2, Suzhou, Peoples R China

[4] Soochow Univ, Zhangjiagang Hosp, Suzhou, Peoples R China

[5] Zhangjiagang Hosp Tradit Chinese Med, Suzhou, Peoples R China

[6] Soochow Univ, Suzhou Hosp 9, Suzhou, Peoples R China

[7] Third Peoples Hosp Kunshan, Dept Hematol, Kunshan, Peoples R China

来源：

关键词：

D O I：

10.1182/blood-2024-210102

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6992 / 6993

页数：2